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Protein-altering variants associated with body mass index implicate pathways that 
control energy intake and expenditure underpinning obesity 
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ABSTRACT 
Genome-wide association studies (GWAS) have identified >250 loci for body mass index (BMI), 
implicating pathways related to neuronal biology. Most GWAS loci represent clusters of common, non-
coding variants from which pinpointing causal genes remains challenging. Here, we combined data from 
718,734 individuals to discover rare and low-frequency (MAF<5%) coding variants associated with BMI. 
We identified 14 coding variants in 13 genes, of which eight in genes (ZBTB7B, ACHE, RAPGEF3, RAB21, 
ZFHX3, ENTPD6, ZFR2, ZNF169) newly implicated in human obesity, two (MC4R, KSR2) previously 
observed in extreme obesity, and two variants in GIPR. Effect sizes of rare variants are ~10 times larger 
than of common variants, with the largest effect observed in carriers of an MC4R stop-codon (p.Tyr35Ter, 
MAF=0.01%), weighing ~7kg more than non-carriers. Pathway analyses confirmed enrichment of neuronal 
genes and provide new evidence for adipocyte and energy expenditure biology, widening the potential of 
genetically-supported therapeutic targets to treat obesity.   
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Obesity is a heritable disease and represents a major unmet public health problem with only a few safe and 
long-term effective therapies1 and intervention strategies2. To understand the genetic basis of obesity and 
identify potential targets for new therapies, genome-wide association studies (GWAS) for body mass index 
(BMI) and obesity risk have identified >250 common variants over the past decade3-7. Consistent with 
single-gene disorders of obesity8, tissue expression and gene-set enrichment analyses for genes in BMI-
associated loci have shown that the central nervous system (CNS) plays a critical role in body weight 
regulation5. While the numerous GWAS loci have provided insight into broad biological mechanisms 
underlying body weight regulation, pinpointing the causal gene(s)/variant(s) remains a major challenge9, as 
GWAS-identified variants are typically non-coding and may affect genes at long distance. The association 
of intronic FTO variants with BMI illustrates the challenges of identifying causal regulatory effects. The 
proposed causal variant was found to regulate the expression of nearby RPGRIP1L in some studies10-12, 
whereas others found that it regulates distant IRX3/IRX5 genes in specific cell types13,14. 
To expedite mapping of obesity-related genes, we performed an exome-wide search for low-
frequency (LF, minor allele frequency [MAF]=1-5%) and rare (R, MAF<1%) single nucleotide variants 
(SNVs) associated with BMI using exome-targeted genotyping arrays. A total of 125 studies 
(Nindividuals=718,734) performed single-variant association between up to 246,328 SNVs and BMI. In 
addition, we performed gene-based meta-analyses to aggregate rare and LF (R/LF) coding SNVs across 
14,541 genes. Using genetic, functional and computational follow-up analyses, we gained insights into the 
function of BMI-implicated genes, and the biological pathways through which they may influence body 
weight.  
 
RESULTS 
Fourteen rare and low-frequency coding variants in 13 genes 
Our study comprises a discovery and a follow-up stage (Supplementary Figure 1, Supplementary Tables 
1-3, Online Methods). In our primary analysis, the discovery stage includes data from 123 studies 
(Nmax=526,508) across five ancestry groups, predominantly European (~85%). Each study performed 
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single-variant association analyses of coding variants present on the exome array, including up to 13,786 
common (MAF>5%) and 215,917 R/LF coding SNVs (exons and splicing sites). Summary statistics were 
combined using fixed-effect meta-analyses. SNV-associations of R/LF variants that reached suggestive 
significance (P<2.0x10-6) were taken forward for follow-up in two European cohorts, deCODE 
(Nmax=72,613) and UK Biobank (Nmax=119,613 [interim release]). Overall significance was assessed after 
combining results of discovery and follow-up studies into a final meta-analysis (all-ancestries, sex-
combined, additive model, Nmax=718,734), SNV-associations that reached P<2x10-7 were considered array-
wide significant15,16 (Table 1, Supplementary Table 4, Supplementary Figures 2-4). In secondary 
analyses, we performed sex-specific analyses, analyses limited to individuals of European ancestry, and 
analyses using a recessive model.  
In our primary analysis of R/LF variants, we identified five rare SNVs in three genes (KSR2, 2 in 
MC4R, 2 in GIPR) and nine LF SNVs in eight genes (ZBTB7B, 2 in ACHE, RAPGEF3, PRKAG1, RAB21, 
HIP1R, ZFHX3, ENTPD6) (Table 1, Box 1, Supplementary Table 5, Supplementary Figure 3a). In 
secondary analyses, we identified two additional LF SNVs, one in all-ancestry women-only (ZFR2) and 
one in European ancestry only analyses (ZNF169) (Table 1, Supplementary Tables 6-8, Supplementary 
Figures 3b, 3c). Of these 16 SNVs, located in 13 genes, the two SNVs in MC4R (r2=1, D’=1) and two in 
ACHE (r2=0.98, D’=0.99) were in high LD, whereas the two SNVs in GIPR (r2=0, D’=0.16) were 
independent of each other. Hence, the 16 SNVs represent 14 independent SNVs (4 rare, 10 LF), of which 
eight locate in genes not previously implicated in BMI (ZBTB7B, ACHE, RAPGEF3, RAB21, ZFHX3, 
ENTPD6, ZFR2, ZNF169), and six are located in five loci that were previously identified by GWAS 
(PRKAG1/BCDIN3D, HIP1R/CLIP1, MC4R, GIPR/QPCTL)5 and/or through sequencing of severe early-
onset obesity cases (MC4R, KSR2)17-19 (Supplementary Figure 5). Conditional analyses established that 
coding SNVs in PRKAG1, MC4R and GIPR are independent of the common lead variants in GWAS loci 
(rs7138803, rs17782313, rs2287019, respectively), whereas the SNV in HIP1R and GWAS locus near 
CLIP1 (rs11057405) represent the same signal (Online Methods, Supplementary Tables 9, 10, 
Supplementary Figure 5).  
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Next, we performed gene-based association tests (SKAT, VT, broad, strict) in up to 14,541 genes20 
to examine whether these aggregated analyses would yield new evidence for multiple R/LF coding SNVs 
in the same gene affecting BMI (Online Methods). Using broad SNV inclusion criteria, associations for 
13 genes reached array-wide significance (P<2.5x10-6)15,16, four of which had not been highlighted in 
single-variant analyses (Table 2, Supplementary Table 11). Conditional analyses showed that only for 
GIPR was the gene-based association driven by multiple SNVs (Table 2, Supplementary Table 12). For 
all other genes, associations were driven by a single SNV only, but these SNVs had not reached array-wide 
significance in single-variant analyses. 
Taken together, we identified 14 R/LF coding SNVs in 13 genes that are independently associated 
with BMI, four rare SNVs in three genes, and 10 LF SNVs in 10 genes. One SNV (ZFR2) showed a sex-
specific effect, whereas no ancestry-specific effects were observed (Supplementary Note, Supplementary 
Tables 6-8, Supplementary Figure 6). Eight (ACHE, ENTPD6, RAB21, RAPGEF3, ZBTB7B, ZFHX3, 
ZFR2, ZNF169) of these 13 genes have not been previously implicated in body weight regulation (Table 
1). 
Novel common coding variants associated with BMI  
Although the main focus of our study was on R/LF coding SNVs, we also identified 92 common coding 
variants (P<2.0x10-7, Supplementary Tables 4, Supplementary Figures 4, 7), of which 41 were novel 
(Supplementary Table 9, Supplementary Note). These novel common loci had not been identified in 
previous GWAS efforts, because our current sample size is more than twice as large as the most recent 
GWAS meta-analysis5, and also because some SNVs were not tested before, as they were not present on 
the HapMap reference panel and/or were on the X-chromosome, which was not analyzed. Because of the 
increased samples size, effect sizes of the 41 novel common loci are smaller (on average 0.014 SD/allele, 
[range: 0.010–0.024]) than of previously established common loci (0.021 SD/allele, [0.010–0.050]) 
(Supplementary Figure 7).  
Impact of R/LF SNVs on BMI and obesity risk  
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The minor allele for half of the 14 R/LF SNVs is associated with lower BMI (Table 1, Figure 1). The 
effects of LF SNVs range between 0.024 and 0.066 SD/allele, equivalent to ~0.11 to 0.30 kg/m2 in BMI or 
~0.315 to 0.864 kg in body weight for a 1.7m tall person. Effects of rare SNVs range between 0.06 and 
0.54 SD per allele, equivalent to 0.26 to 2.44 kg/m2 or 0.74 kg to 7.05 kg per allele (Table 1, Figure 1). By 
comparison, these rare SNV effect sizes are on average ten times larger than those for previously identified 
GWAS loci (effectmean=0.019 SD/allele, ~0.086 kg/m2 or ~0.247 kg/allele) of which the largest effect is 
seen for the FTO locus (0.08 SD/allele, ~0.35 kg/m2 or 1 kg/allele) and those for other GWAS loci range 
between 0.010 and 0.056 SD/allele (~0.045 to 0.25 kg/m2, or 0.130 to 0.728 kg)5. 
Effect sizes increase as MAF decreases, in particular for SNVs with a MAF<0.5% (~1 heterozygote 
carrier in 100 people), consistent with the statistical power of our sample (Figure 1). For example, the 
nonsense p.Tyr35Ter MC4R SNV (rs13447324, MAF=0.01%) is present in ~1 in 5,000 individuals and 
results in a ~7 kg higher body weight for a 1.7m tall person. The two GIPR SNVs contribute independently 
to a lower body weight, carriers (1 in ~455 individuals) of p.Arg190Gln (rs139215588) weigh ~1.92 kg 
(0.148 SD BMI) less than non-carriers and carriers (1 in ~385 individuals) of p.Glu288Gly (rs143430880) 
weigh ~1.99 kg (0.153 SD BMI) less. Among 115,611 individuals of the UK Biobank, one apparently 
healthy 61-year-old woman, with no reported illnesses, carried both rare GIPR alleles and weighed ~11.2 
kg less (equivalent to -0.86 SD BMI or 3.87 kg/m2) than the average non-carrier of the same height 
(Supplementary Figure 8). The possible synergistic effect of the two GIPR alleles needs confirmation by 
additional individuals that carry both variants.  
Even though effect sizes of LF and, in particular, rare SNVs tend to be larger than those of common 
GWAS-identified loci5, the 14 SNVs combined explain <0.1% of BMI variation, because of their low 
population frequency (Table 1, Online Methods). Also, although the effects of the four rare SNVs (KSR2, 
MC4R, 2 in GIPR) are large by GWAS standards, penetrance for obesity is still expected to be low. Indeed, 
using data from the UK Biobank (Nmax=119,781), we compared the prevalence of normal-weight (18.5 
kg/m2 ≤ BMI < 25 kg/m2) and obesity (BMI ≥ 30 kg/m2) between carriers and non-carriers (Supplementary 
Table 13, Online Methods). For GIPR (p.Arg190Gln, p.Glu288Gly), both BMI-decreasing SNVs, carriers 
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tended (P<0.05) to have a lower obesity prevalence (21.2%, 20.1%, respectively), compared to non-carriers 
(25.1%, 25%). For MC4R p.Tyr35Ter and KSR2 p.Arg525Gln, the prevalence of obesity between carriers 
(30%, 25.7%, resp.) and non-carriers (25.1%, 25.3%) was not significantly different. 
We examined whether R/LF SNVs affect obesity risk early on in life by combining data from three 
case-controls studies of childhood obesity (Ncases=4,395, Ncontrols=13,072) (Online Methods, 
Supplementary Table 14). Associations for 10 of 13 SNVs were directionally consistent with those 
observed for BMI in adults (77%, Pbinomial=0.046), three of which (ZBTB7B, PRKAG1, RAB21) reached 
nominal significance (P<0.05). While no carriers of the MC4R mutations were available for analyses, the 
role of MC4R in body weight regulation in childhood was established almost two decades ago17,19,21. 
Impact of R/LF SNVs on cardiometabolic and other traits 
To examine whether identified SNVs affect other traits, we obtained results from multiple large-scale 
genetic consortia (GIANT15, MAGIC, GoT2D/T2D-GENES16, GLGC, ICBP22, REPROGEN23) 
(Supplementary Table 15, Supplementary Figure 9), and performed phenome-wide association 
(PheWAS) analyses using electronic medical record (EMR) data from BioVu and UK Biobank (Online 
Methods, Supplementary Table 16). The BMI-increasing allele of ZBTB7B p.Pro190Ser is associated 
with greater height, and those of PRKAG1, ACHE, and RAPGEF3 SNVs are associated with shorter height, 
but association with other traits differ. Specifically, PRKAG1 p.Thr38Ser Ser-allele carriers appear heavier 
and shorter, have lower HDL-cholesterol levels, earlier age at menarche (reported before23) and higher 
systolic blood pressure, which is in agreement with PheWAS analyses showing an increased risk of 
“malignant essential hypertension” and “hypertension” (Supplementary Table 16). While carriers of the 
RAPGEF3 p.Leu300Pro Pro-allele are also heavier and shorter, they have a lower WHRadjBMI24 and lower 
fasting insulin levels (Supplementary Table 15), consistent with PheWAS results that show lower odds of 
“secondary diabetes mellitus” (Supplementary Table 16). Thus, while all SNVs are associated with BMI, 
their patterns of association with other traits suggest they may affect different physiological pathways.  
Gene set enrichment analyses  
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To test whether the R/LF variants implicate biological pathways, we performed gene set enrichment 
analyses. Similar to our previous analysis of GWAS for BMI5, we analyzed coding variants that reached 
P<5x10-4, using a DEPICT version adapted for exome-array analysis15 (Online Methods, Supplementary 
Note). We used 50 R/LF coding variants as input (all P<5x10-4, Online Methods) and observed significant 
enrichment (Figure 2, Supplementary Table 17, Supplementary Figure 10a). Many of these relate to 
neuronal processes, such as neurotransmitter release and synaptic function (e.g. glutamate receptor activity, 
regulation of neurotransmitter levels, synapse part), consistent with previous findings from GWAS5. When 
we excluded variants near (+/- 1Mb) previously identified GWAS loci, we still observed 29 significantly 
enriched gene sets (in 12 meta-gene sets) (Supplementary Table 18, Supplementary Figure 10b), thereby 
providing an independent confirmation of the GWAS gene set enrichment results. In addition to neuronal-
related gene sets, the analyses with R/LF coding variants newly identified a cluster of metabolic pathways 
related to insulin action and adipocyte/lipid metabolism (e.g. enhanced lipolysis, abnormal lipid 
homeostasis, increased circulating insulin level, Figure 2). Finally, we observed that R/LF BMI-associated 
coding variants are more effective at identifying enriched gene sets compared to common coding variants. 
Specifically, adding 192 common coding SNVs (all P<5x10-4) to the analysis decreased the number of 
enriched gene sets from 471 (106 meta-gene sets) seen with R/LF coding SNVs to 62 (24 meta-gene sets) 
(Supplementary Table 19, Supplementary Figure 10c). We observed fewer significant genes sets with 
the combined common and R/LF analysis, despite including more total coding variants and a higher fraction 
of array-wide significant coding variants. One possible explanation is that R/LF coding variants may fall in 
the causal gene more often than do common coding variants, which suggests that the R/LF variants are 
more likely to be causal, rather than simply in LD with causal variants.  
We also used gene set enrichment analysis to prioritize candidate genes. Among the genes with 
R/LF coding variants associated with BMI at P<5x10-4, a subset is prominently represented in the CNS-
related enriched gene sets (Figure 2) and is proposed to influence neurotransmission and/or synaptic 
organization, function and plasticity. These include genes in regions with suggestive evidence of association 
from GWAS (e.g. CARTPT, MAP1A, ERC2) and genes in regions not previously implicated by GWAS 
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(e.g. CALY, ACHE, PTPRD, GRIN2A). The non-neuronal metabolic gene sets implicate two genes (CIDEA, 
ADH1B) that are markers of brown or “beige” adipose tissue25,26, providing new supporting evidence for a 
causal role of this aspect of adipocyte biology.  
Drosophila fly results  
To test for potential adiposity-driving effects of gene regulation, we performed tissue-specific RNAi-
knockdown experiments in Drosophila. We generated adipose-tissue (cg-Gal4) and neuronal (elav-Gal4) 
specific RNAi-knockdown crosses for nine of the 13 candidate genes for which fly orthologues exist 
(Supplementary Table 20) and performed whole body triglyceride analysis in young adult male flies. 
Triglycerides, the major lipid storage form in animals, were chosen as a direct measure of fly adiposity. 
Both neuronal and fat-body knockdown of zfh2, the orthologue of ZFHX3, resulted in significantly 
increased triglyceride levels. Adipose-tissue specific, but not neuronal, knockdown of epac (RAPGEF3) 
was lethal. Tissue-specific loss-of-function of the other seven genes tested did not affect triglyceride levels. 
R/LF coding SNVs in monogenic and syndromic genes  
We identified 39 genes in the literature that have been convincingly implicated in monogenic obesity or 
syndromes of which obesity is one of the main features (Supplementary Table 21, 22, Supplementary 
Figure 11). Of the 652 R/LF SNVs in these 39 monogenic and/or syndromic genes, five R/LF SNVs were 
significantly associated with BMI (Bonferroni-corrected P-value = 7.7x10-5 (=0.05/652)). Beside SNVs in 
MC4R (p.Tyr35Ter, Asp37Val) and KSR2 (Arg525Gln), already highlighted in the single-variant analyses, 
we identified an additional SNV in MC4R (p.Ile251Leu) and one in BDNF (p.Glu6Lys). MC4R p.Ile251Leu 
has been previously shown to protect against obesity27, whereas BDNF p.Glu6Lys, independent of 
previously GWAS-identified SNVs (r2=0.01, D’=1.0)5, has not been implicated in body weight regulation 
before. We examined whether the 652 R/LF SNVs showed enrichment for association with BMI compared 
to R/LF coding SNVs in all other genes, but found no evidence to support this. 
 
DISCUSSION  
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In this meta-analysis of exome-targeted genotyping data, we identified 14 R/LF coding variants in 13 genes 
associated with BMI. Eight of these genes (ACHE, ENTPD6, RAB21, RAPGEF3, ZBTB7B, ZFHX3, ZFR2, 
ZNF169) have not been previously implicated in human obesity, but evidence from animal studies provides 
support for a role in energy metabolism for some of these, such as ACHE28,29, RAPGEF330-33, and 
PRKAG134-39. Others fall into established BMI GWAS loci (PRKAG1/BCDIN3D, HIP1R/CLIP1, MC4R, 
GIPR/QPCTL)5 and/or were previously implicated in severe early-onset obesity (MC4R, KSR2)17-19 and 
using this exome-targeted approach, we pinpoint R/LF variants in these loci that play a role in obesity in 
the general population. Pathway analyses confirm a key role for neuronal processes, and newly implicate 
adipocyte and energy expenditure biology.  
 Consistent with other polygenic traits15,23,40-43, we show that large sample sizes are needed to 
identify R/LF variants. Observed effect sizes reflect the statistical power of our sample size, and are 
particularly large for SNVs with a MAF < 0.05%. The existence of rare alleles with larger effects on 
BMI than have been observed for common alleles might reflect negative or stabilizing selection 
on the extremes of BMI. However, rare variants with smaller effects almost certainly exist, larger 
samples will be needed to uncover these. Our study was limited to coding variants on the exome-array, 
large-scale sequencing studies will be needed to test for variants not covered by exome-arrays. 
The strongest association was observed for a stop-codon (p.Tyr35Ter, rs13447324, MAF= 0.01%) 
in MC4R, with carriers weighing on average 7kg more than non-carriers. MC4R is widely expressed in the 
CNS and is an established key player in energy balance regulation44,45. Mouse and human studies showed 
already two decades ago that MC4R-deficiency results in extreme obesity, mainly through increased food 
intake46-49. p.Tyr35Ter, which results in MC4R-deficiency51, was one of the first MC4R mutations 
discovered in monogenic cases of obesity17,19, in whom the mutation is >20x more prevalent than in the 
general population17,50,52,53. Here, we show that p.Tyr35Ter plays a role outside the setting of early-onset 
and extreme obesity. Despite its large effect, penetrance is low, and does not fit the model of a fully 
penetrant Mendelian variant.  
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While significant R/LF coding variants are strong candidates for being causal, the strongest 
implication of causal genes is provided by association with multiple independent coding variants, as we 
demonstrate for GIPR. We identified two rare variants in GIPR (p.Arg190Gln, rs139215588, MAF=0.11%, 
p.Glu288Gly, rs143430880, MAF=0.13%) independently associated with lower BMI, carriers of either 
variant weigh ~2 kg less than non-carriers. Common variants in/near GIPR have been found to associate 
with lower BMI55 and delayed glucose and insulin response to an oral glucose challenge54. However, the 
two rare variants influence BMI independently of these common ones and are not associated with type 2 
diabetes or glycemic traits tested. Rodent models have provided strong evidence for a role of GIPR in body 
weight regulation. Gipr-deficient mice are protected from diet-induced obesity56 and have an increased 
resting metabolic rate57. Blocking GIP-signaling using a vaccination approach in mice on a high-fat diet 
reduces weight gain, mainly through reduced fat accumulation, mediated through increased energy 
expenditure58. Manipulation of incretins (GIP, GLP1) and their receptors has complex effects on obesity 
and insulin secretion/action that may differ between human and mice59. The human genetic data suggest 
that inhibition of GIPR-signaling might present a therapeutic target for the treatment of obesity60.  
A fourth rare variant, in KSR2, (p.Arg525Gln, rs56214831, MAF=0.82%) increases body weight 
by ~740g/allele. KSR2 is another gene previously implicated in energy metabolism and obesity18,61,62. In a 
recent study, mutation carriers were hyperphagic, had a reduced basal metabolic rate and severe insulin 
resistance18. Consistent with human data, Ksr2-/- mice were obese, hyperphagic, and had a reduced energy 
expenditure18,61-63. KSR2 is almost exclusively expressed in the brain and interacts with multiple proteins64, 
including AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis61,62. Interestingly, 
KSR2 is one of the first genes implicated in severe, early-onset obesity in which mutations not only affect 
food intake but also basal metabolic rate, and is thought to act via neuronal effects18 (Figure 2).  
Despite convincing associations of these four rare variants in MC4R, GIPR and KSR2, their 
penetrance for obesity is low (Supplementary Table 13). This is consistent with the polygenic and 
multifactorial nature of obesity, where variants across a range of frequencies and effect sizes contribute to 
the phenotype in any one person. Despite low predictive power, it remains possible that the identities of 
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particular variants in any one person may contribute to different balances of underlying physiologies and 
hence, different responses to treatments. This was illustrated in two patients with monogenic obesity due 
to POMC mutations, these patients lack the main activator of MC4R and were effectively treated with an 
MC4R-agonist65.  
Of the coding variants in newly identified genes, some have well-known connections to obesity. 
For example, PRKAG1 encodes the γ1-subunit of AMPK, a critical cellular energy sensor34. In the 
hypothalamus, AMPK integrates hormonal and nutritional signals with neuronal networks to regulate food 
intake and whole-body energy metabolism35-37. Furthermore, hypothalamic AMPK is a key regulator of 
brown adipose tissue in mice36,38,39. The BMI-decreasing allele at the associated PRKAG1 variant 
(p.Thr38Ser, rs1126930, MAF=3.22%) has additional beneficial effects on blood pressure, providing 
additional genetic support for modulation of AMPK as an ongoing therapeutic avenue for treatment.  
ACHE, in which p.His353Asn (rs1799805, MAF=3.9%) is associated with increased BMI, is 
another candidate gene related to neuronal biology, involved in the signaling of acetylcholine at 
neuromuscular junction and brain cholinergic synapses67,68. Inhibitors of ACHE, used to treat moderate-to-
severe Alzheimer’s Disease69, results in weight loss in humans and Ache-deficient mice have delayed 
weight gain28,29. However, these may be indirect consequences of adverse gastrointestinal and 
neuromuscular effects, respectively28,29,70,71.  
Another LF coding variant (p.Leu300Pro, rs145878042, MAF=1.1%) is located in RAPGEF3, and 
has strong effects on multiple other phenotypes. The BMI-increasing 300Pro-allele is associated with 
shorter height, lower WHRadjBMI and lower insulin levels, suggesting that this variant has multiple 
physiologic consequences. Data from animal models also suggest complex effects of RAPGEF3 on 
adipocyte biology, energy balance and glucose metabolism30-33. For example, in one study, global deletion 
of Rapgef3 in mice on a high-fat diet are resistant to obesity due to reduced food intake and have an 
increased glucose tolerance31. However, in a similar study, Rapgef3-/- mice develop severe obesity, 
increased respiratory exchange ratio and impaired glucose tolerance33. Adipose tissue-specific Rapgef3 
knockout mice on a high-fat diet are also more prone to obesity, show increased food intake, reduced energy 
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expenditure, impaired glucose tolerance, and reduced circulating leptin levels72. More research is needed to 
understand the consequences of RAPGEF3 manipulation. 
The remaining genes with significant associations, ENTPD6, HIP1R, RAB21, ZFR2, ZBTB7, and 
ZFHX3, have no clear prior evidence for a role in energy homeostasis, and in-depth functional follow up is 
needed to gain insight in how they affect body weight. Here, we performed gene set enrichment analyses 
to better understand the biology implicated by our genetic data, and confirm the importance of neuronal 
processes, in particular synaptic function and neurotransmitter release, providing an independent validation 
of previous GWAS findings5. The combination of gene set enrichment and association analyses of coding 
variants also enables us to highlight candidate genes that are both within these gene sets and show 
association with BMI at R/LF coding variants. These include genes reaching array-wide significance (e.g. 
ACHE, ZFR2), and others with clear prior evidence for a role in body weight regulation (e.g. CARTPT73), 
but that had not been highlighted in our single-variant or gene-based association analyses. Of note, the 
enrichment signals were stronger with R/LF coding variants only than with all coding variants, suggesting 
that R/LF variants are more likely to be causal and may more often point directly to relevant genes, whereas 
common coding variants may more often be proxies for common noncoding variants that affect nearby 
genes. 
 In addition, our gene set enrichment analyses now provide supporting evidence for a role of non-
neuronal mechanisms as well. Specifically, CIDEA and ADH1B are both strongly predicted to be members 
of enriched gene sets related to insulin action and adipocyte biology, and both are markers that distinguish 
brown from white fat depots in mice25 and humans26. CIDEA is predominantly expressed in adipose tissue 
and known as a key regulator of energy metabolism25. Cidea-deficient mice are resistance to diet-induced 
obesity with increased lipolysis and mitochondrial uncoupling25. The connection of ADH1B to obesity is 
less clear, but the gene is highly expressed in human adipocytes, has been implicated by gene expression 
analyses in obesity and insulin resistance, and functions early in a potentially relevant metabolic pathway 
(retinoid biosynthesis)25,26,74,75. Similar pathways were implicated by recent work dissecting the signal near 
FTO13. However, because SNV-association signals at ADH1B and CIDEA did not reache array-wide 
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significance, additional genetic analysis of their role in obesity would be warranted.  
In summary, we performed association analyses between R/LF variants and BMI in >700,000 
individuals, and identified 14 variants in 13 genes, in 5 known and 8 novel genes. While each variant 
contributes little to BMI variation in the general population, they may have substantial impact on body 
weight at an individual level. Furthermore, prior literature for these genes and unbiased gene set enrichment 
analysis indicate a strong role for neuronal biology and also provide new support for a causal role of aspects 
of adipocyte biology. The identified genes provide potential targets that may lead to new and more precise 
approaches for the treatment of obesity, which has seen minimal innovation in the past 30 years1. 
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FIGURE LEGENDS 
Figure 1. Effect sizes (y-axis) of the 14 BMI-associated R/LF coding variants by their minor allele 
frequency. Effect sizes are expressed in body weight (kg) per allele, assuming a SD of 4.5 kg and an 
average-sized person of 1.7m tall. Solid markers indicate that the minor allele is associated with higher 
BMI, and clear markers indicate that the minor allele is associated with lower BMI. Variants were identified 
in all-ancestry analyses (light blue diamonds), the European ancestry analyses (dark blue square) and 
women-only analyses (pink diamond). Effect sizes for previously identified GWAS loci are shown in navy 
blue diamonds. The dotted line represents 80% power, assuming α = 2x10-7 and N= 525,000 (discovery 
sample size). 
 
Figure 2. Heatmap showing DEPICT gene set enrichment results for suggestive and significant rare 
and low-frequency coding SNVs. For any given square, the color indicates how strongly the corresponding 
gene (x-axis) is predicted to belong to the reconstituted gene set (y-axis), based on the gene’s Z-score for 
gene set inclusion in DEPICT’s reconstituted gene sets (red indicates a higher, blue a lower Z-score). To 
visually reduce redundancy and increase clarity, we chose one representative "meta-gene set" for each 
group of highly correlated gene sets based on affinity propagation clustering (Online Methods, 
Supplementary Note). Heatmap intensity and DEPICT P-values (Supplementary Table 17) correspond 
to the most significantly enriched gene set within the meta-gene set. Annotations for genes indicate (1) 
whether it has an OMIM annotation as underlying a monogenic obesity disorder (black/grey), (2) the MAF 
of the significant ExomeChip (EC) variant (blue), (3) whether the variant’s P-value reached array-wide 
significance (<2x10-7) or suggestive significance (<5x10-4) (purple), (4) whether the variant was novel, 
overlapping “relaxed” GWAS signals from Locke et al.5 (GWAS P<5x10-4), or overlapping “stringent” 
GWAS hits (GWAS P<5x10-8) (pink), and (5) whether the gene was included in the gene set enrichment 
analysis or excluded by filters (orange/brown) (Online Methods, Supplementary Note). Annotations for 
gene sets indicate if the meta-gene set was significant (green, FDR <0.01, <0.05, or not significant) in the 
DEPICT analysis of GWAS results5. Here, two regions of particularly strong gene set membership are 
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shown (see full heat map in Supplementary Figure 10a). 
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TABLES 
Table 1 Rare and low-frequency coding variants significantly associated with BMI 
Chr:position Variant Coding 
locus 
Allele Amino acid 
change 
EAF 
(%) 
β  
(SD/allele) 
SE P-value N Explained 
variance 
(%) 
   Effect Other        
All-ancestries additive           
1:154987704 rs141845046 ZBTB7B* T C p.Pro190Ser 2.44% 0.048 0.006 7.73E-18 718,628 0.011% 
7:100490797 rs1799805 ACHE* T G p.His353Asn 3.90% 0.029 0.005 2.82E-10 707,448 0.006% 
12:48143315 rs145878042 RAPGEF3* G A p.Leu300Pro 1.10% 0.066 0.008 1.56E-15 700,852 0.010% 
12:49399132 rs1126930 PRKAG1 C G p.Thr38Ser 3.22% 0.034 0.005 3.98E-12 712,354 0.007% 
12:72179446 rs61754230 RAB21* T C p.Ser224Phe 1.74% 0.040 0.007 1.33E-09 693,373 0.005% 
12:117977550 rs56214831 KSR2 T C p.Arg525Gln 0.82% 0.057 0.010 1.08E-08 655,049 0.005% 
12:123345509 rs34149579 HIP1R T G p.Cys938Phe 4.54% -0.032 0.004 2.00E-14 716,253 0.009% 
16:72830539 rs62051555 ZFHX3* G C p.Gln1100His 4.34% -0.024 0.004 4.01E-08 690,637 0.005% 
18:58039478 rs13447324 MC4R T G p.Tyr35Ter 0.01% 0.542 0.086 2.26E-10 631,683 0.006% 
19:46178020 rs139215588 GIPR A G p.Arg190Gln 0.11% -0.148 0.028 1.25E-07 695,800 0.005% 
19:46180976 rs143430880 GIPR G A p.Glu288Gly 0.13% -0.153 0.028 2.96E-08 599,574 0.006% 
20:25195509 rs6050446 ENTPD6* A G p.Lys185Glu 2.71% -0.034 0.005 2.40E-10 717,084 0.006% 
All-ancestries sex-specific additive (women only)         
19:3813906 rs45465594 ZFR2* C A p.Ile718Met 2.55% -0.040 0.008 1.94E-07 373,848 0.008% 
European Ancestry additive            
9:97062981 rs12236219 ZNF169* T C p.Arg381Cys 4.23% -0.029 0.005 8.78E-10 612,396 0.007% 
Array-wide significant is defined as P < 2x10-7.            
Variant positions are reported according to Build 37 and their alleles are coded based on the positive strand.  
Alleles (effect/other), effect allele frequency (EAF), beta (b), standard error (SE) and P values are based on the meta-analysis of Discovery Stage (GIANT) 
and Validations stage (deCODE, UKBiobank) studies. Effect allele is always the minor allele. Effects (b) are expressed in SD, assuming mean=0 and SD=1.
            
The amino acid change from the most abundant coding transcript is shown in this table (see Supplementary Table 25 for more details on protein annotation 
based on VEP tool and transcript abundance from GTEx database).         
* Novel gene, i.e. not previously implicated in human obesity            
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Table 2. Genes significantly associated with BMI in a gene-based meta-analyses, aggregating R/LF coding SNVs 
Gene Location longest coding 
transcript 
Testd N 
variants 
P-value Conditioned P-
valuea 
Single variant  
       Top variant P-value 
All-ancestries sex-combined        
SLC6A17 chr1:110693132-110744823 SKAT 13 2.73E-07 0.13  rs41313405 4.45E-07 
RAPGEF3 chr12:48128453-48152889 SKAT 19 8.91E-15 0.20  rs145878042 5.16E-14 
PRKAG1 chr12:49396055-49412629 SKAT 4 2.75E-12 0.53  rs1126930 2.63E-12 
RAB21 chr12:72148643-72187256 SKAT 5 4.81E-08 0.27  rs61754230 4.96E-08 
KSR2 chr12:117890817-118406028 SKAT 7 7.15E-09 0.19  rs56214831 4.59E-08 
MAP1A chr15:43809806-43823818 SKAT 25 9.42E-07 0.16  rs55707100 1.01E-06 
MC4R chr18:58038564-58040001 VT 4 3.72E-09 0.01  rs13447325 2.97E-11 
GIPR chr19:46171502-46186982 VT 10 8.24E-09 1.12E-04  rs143430880 5.76E-06 
All-ancestries sex-specific        
ALDH3A1 (men only) chr17:19641298-19651746 SKAT 15 3.24E-07 0.003  rs142078447 8.62E-06 
ZFR2 (women only) chr19:3804022-3869027 SKAT 19 1.81E-07 0.82  rs45465594 3.64E-07 
European sex-combined        
ACHE chr7:100487615-100493592 SKAT 6 3.30E-10 0.12  rs386545548 7.22E-10 
European sex-specific         
ANGPTL7 (men only) chr1:11249346-11256038  VT 3 2.50E-06 0.008  rs202182115 2.56E-05 
ZNF169 (women only) chr9:97021548-97064111 SKAT 9 1.89E-07 0.24  rs12236219 1.06E-06 
Array-wide significant gene-based association is defined as P<2.5x10-6. P-values are based on the meta-analysis of Discovery Stage studies. 
Gene-based analyses were performed with SKAT and VT, results shown are from the test (SKAT or VT) for which the significance exceeded 
P<2.5x10-6. Only results using the "broad" SNV inclusion criteria reached array-wide significance. 
Transcript positions are reported according to Build 37 for the longest coding transcript supported by RefSeq (as displayed in USCS Genome 
Browser).  
aP-value after conditioning on the most significant (top) single variant aggregated in the gene-based test. 
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BOX 1 – Brief description of the 13 genes (alphabetical) identified  
ACHE (acetylcholinesterase). ACHE is mainly expressed in brain and muscle76. Its encoded protein 
hydrolyzes acetylcholine (Ach) at brain cholinergic synapses and neuromuscular junctions, and thus 
terminates signal transmission67. Knockout mice showed a reduction in expression of muscarinic Ach 
receptors in brain regions associated with learning and memory and showed lower ability to initiate the 
signaling cascade77. This gene has fewer missense variants than expected and is highly intolerant to loss of 
function (LoF) mutations52. 
ENTPD6 (ectonucleoside triphosphate diphosphohydrolase 6). Previously known as Interleukin 6 Signal 
Transducer-2, this gene is similar to E-type nucleotidases that participate in purine and pyrimidine 
metabolism, calcium ion binding, hydrolase activity, magnesium ion binding and nucleoside-diphosphatase 
activity78. It is widely expressed in many different tissues, in particular in the brain76.  
GIPR (gastric inhibitory polypeptide receptor). GIPR encodes a G-protein coupled receptor for gastric 
inhibitory polypeptide that is secreted by intestinal K-cells after food ingestion59. GIPR activation 
stimulates insulin secretion from pancreatic β-cells and mediates fat deposition by increasing lipoprotein 
lipase activity, lipogenesis, fatty acid and glucose uptake in adipocytes. GIPR is mostly expressed in EBV-
transformed lymphocytes, stomach and visceral adipose tissue76.  
HIP1R (huntingtin interacting protein 1 related). HIP1R is a multi-domain protein that promotes actin 
binding and cell survival and interacts with CLTB and HIP1 (GeneCards). HIP1 and HIP1R appear to play 
central roles in clathrin-coated vesicle formation and intracellular membrane trafficking by promoting 
transient interaction between actin filaments and the endocytic machinery79,80. HIP1R is most expressed in 
the stomach tissue, brain (substantia nigra, spinal cord, hippocampus), and sun-exposed skin 76.  
KSR2 (kinase suppressor of ras 2). KSR2 is an intracellular protein that functions as a molecular scaffold 
to regulate MAP kinases ERK1/2 and determine cell fates. KSR2 also regulates AMPK activity controlling 
cellular thermogenesis, fat oxidation, and glucose metabolism18,61,62. Knockout mouse models and human 
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mutations have been linked to obesity risk62. KSR2 is almost exclusively expressed in the brain. It has fewer 
missense variants than expected and is highly intolerant to LoF mutations52. 
MC4R (melanocortin 4 receptor). MC4R is a seven-transmembrane G-protein coupled receptor, 
predominantly expressed in the brain76. MC4R has been known to play a key role in body weight regulation 
for more than 20 years. Activation of MC4R by α-MSH, a POMC-derived peptide, suppresses food intake, 
MC4R antagonists increase food intake and MC4R deficiency in human and rodent models results in 
hyperphagia and severe and early-onset obesity81. More than 150 MC4R mutations have been identified in 
individuals with severe, early-onset obesity81, many of which lead to a complete or partial loss of 
function82,83. Up to 6% of individuals with severe, early-onset obesity carry pathogenic mutations in MC4R, 
making MC4R deficiency the most common form of monogenic obesity82,84. 
PRKAG1 (protein kinase AMP-activated non-catalytic subunit gamma 1). The protein encoded by 
PRKAG1 is one of the gamma regulatory subunits of the AMP-activated protein kinase (AMPK), which is 
an important energy-sensing enzyme that monitors cellular energy status34. AMPK and PRKAG1 are 
ubiquitously expressed76. In the hypothalamus, AMPK influences food intake, energy expenditure and 
glucose homeostasis36. Muscle-specific overexpression of AMPK γ1 subunit in mice results in increased 
food intake, but does not affect body weight, presumably through a compensatory increased energy 
expenditure85.  
RAB21 (member RAS oncogene family). RAB21 belongs to the Rab family of monomeric GTPases 
involved in the control of cellular membrane traffic. The encoded protein is widely expressed76 and plays a 
role in the targeted trafficking of integrins, and is involved in the regulation of cell adhesion and migration86. 
RAB21 is thought to be intolerant to LoF mutations52.  
RAPGEF3 (rap guanine nucleotide exchange factor 3, also EPAC1). RAPGEF3 encodes the exchange 
protein directly activated by cAMP isoform 1 (EPAC1), one of two cAMP sensors that are involved in 
numerous intracellular cAMP-mediated functions87. EPAC1 is ubiquitously expressed76, and insights from 
mouse knockout models suggest a role in energy homeostasis and the development of obesity and diabetes 
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through the regulation of leptin and insulin signaling31,87. 
ZFR2 (zinc finger RNA binding protein 2). The biological function of the gene product is as yet 
undetermined. GO annotations related to this gene include nucleic acid binding. It may have a role in 
dendritic branching and axon guidance88,89. ZFR2 is predominantly expressed in the brain76.  
ZBTB7B (zinc finger and BTB domain containing 7B, also ThPOK). ZBTB7B is a transcription factor 
regulating T-cell fate in the thymus, particularly as the master regulator of CD4+ lineage 
commitment90. It is a repressor of type 1 collagen gene expression91. This gene is mainly expressed in T-
cell lineages, skin and gastrointestinal tissues. ZBTB7B is thought to be intolerant to LoF mutations52. 
ZFHX3 (zinc finger homeobox 3). ZFHX3 encodes a transcription factor with multiple homeodomains and 
zinc finger motifs and plays a role in cell-cycle, myogenic and neuronal differentiation. This gene is a tumor 
suppressor92 that influences circadian rhythms93,94 and sleep94. It may also contribute to the genesis of atrial 
fibrillation95. ZFHX3 is highly expressed in arterial tissue and also other tissues76. The ZFHX3 gene is 
highly intolerant to LoF mutations52. 
ZNF169 (zinc finger protein 169). The biological function of the gene product is as yet unclear. GO 
annotations suggest that ZNF169 is involved in nucleic acid binding and transcriptional regulation. This 
gene is ubiquitously expressed76.  
More details and references in Supplementary Table 24.  
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ONLINE METHODS 
Study design & participants  
The discovery cohort consisted of 123 studies (163 datasets) comprising 526,508 adult (≥18yrs) individuals 
of the following ancestries (Supplementary Figure 1): 1) European (N = 449,889), 2) South Asian (N = 
29,398), 3) African (N = 27,610), 4) East Asian (N = 8,839), and 5) Hispanic (N = 10,772). All participating 
institutions and coordinating centers approved this project and informed consent was obtained from all 
study participants. Discovery meta-analyses were carried out in each ancestry separately and in the All-
ancestries combined group, for both sex-specific and sex-combined analyses. SNVs for which associations 
reach suggestive significance (P<2.0x10-6) in the discovery analyses, were taken forward for follow-up in 
192,226 individuals of European ancestry from the UK BioBank and deCODE. Conditional analyses were 
conducted in the All-ancestries and European descent groups. Study-specific design, sample quality control 
and descriptive statistics are provided in Supplementary Tables 1-3. 
Phenotype  
Body mass index (BMI: weight [in kilograms] / height [in meters] 2) was corrected for age, age2 and 
genomic principal components (PC, derived from GWAS data, the variants with MAF > 1% on ExomeChip, 
or ancestry informative markers available on the ExomeChip), as well as any additional study-specific 
covariates (e.g. recruiting center), in a linear regression model. For studies with non-related individuals, 
residuals were calculated separately by sex, whereas for family-based studies sex was included as a 
covariate in the model. Additionally, residuals for case/control studies were calculated separately. Finally, 
residuals were subject to inverse normal transformation96. 
Genotype calling  
The majority of studies followed a standardized protocol and performed genotype calling using the 
designated manufacturer software, which was then followed by zCall97. For 10 studies, participating in the 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the raw 
intensity data for the samples from seven genotyping centers were assembled into a single project for joint 
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calling98. Study-specific quality control (QC) measures of the genotyped variants were implemented before 
association analysis (Supplementary Table 2).  
Statistical analyses 
Study-level association analyses. Individual cohorts were analyzed separately for each ancestry, in sex-
combined and sex-specific groups, with either RAREMETALWORKER (see URL links at the end of the 
Online Methods) or RVTEST99 (Supplementary Table 2), to associate inverse normal transformed BMI 
with genotype accounting for potential cryptic relatedness (kinship matrix) in a linear mixed model. These 
software tools are designed to perform score-statistics based rare-variant association analyses, can 
accommodate both unrelated and related individuals, and provide single-variant results and variance-
covariance matrices. The covariance matrix captures linkage disequilibrium (LD) relationships between 
markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses100. Single-variant 
analyses were performed for both additive and recessive models.  
Centralized quality-control. A centralized quality-control procedure, implemented in EasyQC101, was 
applied to individual cohort association summary statistics to identify cohort-specific problems: (1) 
assessment of possible problems in BMI transformation, (2) comparison of allele frequency alignment 
against 1000 Genomes Project phase 1 reference data to pinpoint any potential strand issues, and (3) 
examination of quantile-quantile (QQ) plots per study to identify any problems arising from population 
stratification, cryptic relatedness and genotype biases.  
Meta-analyses. Meta-analyses were carried out by two different analysts at two sites in parallel. We 
excluded variants with a call rate < 95%, Hardy-Weinberg equilibrium P-value < 1×10-7, or large allele 
frequency deviations from reference populations (> 0.6 for all-ancestry analyses and > 0.3 for ancestry-
specific population analyses). Significance for single-variant analyses was defined at the array-wide level 
(a Bonferroni-corrected threshold of P < 2×10-7 for ~250,000 SNVs). To test for sex-differences of the 
significant variants (P < 2×10-7), we calculated the P-diff for each SNP, which tests for differences between 
women-specific and men-specific beta estimates using EasyStrata102. For gene-based analyses, we applied 
Page 47 of 54 
the sequence kernel association test (SKAT)103 and the Variable Threshold (VT)104 gene-based methods 
using two different sets of criteria (broad and strict) to select predicted damaging R/LF variants with MAF 
< 5%, based on coding variant annotation from five prediction algorithms (PolyPhen2 HumDiv and 
HumVar, LRT, MutationTaster and SIFT)20. Our broad gene-based tests included nonsense, stop-loss, 
splice site, and missense variants that are annotated as damaging by at least one algorithm mentioned above. 
Our strict gene-based tests included only nonsense, stop-loss, splice site, and missense variants annotated 
as damaging by all five algorithms. Statistical significance for gene-based tests was set at a Bonferroni-
corrected threshold of P < 2.5×10-6 for about 20,000 genes16,105. Singe-variant and gene-based meta-
analyses were both performed using RareMETALS R-package106. As our secondary analyses are nested 
and/or highly correlated with our primary analysis, we chose the same, already stringent, Bonferroni-
corrected significance threshold for both analyses.  
Genomic inflation. Although the overall λGC value is in the normal range for all coding variants (λGC = 1.1, 
Supplementary Table 23), we observed a marked genomic inflation of the test statistics even after 
adequate control for population stratification (linear mixed model) arising from common markers (λGC = 
1.99, Supplementary Figure 2a and Supplementary Table 23). Such inflation is expected for a highly 
polygenic trait like BMI, as was previously confirmed for height15, and is consistent with our very large 
sample size5,107. Furthermore, some of the inflation may be due to the design of the ExomeChip, which 
besides R/LF coding SNVs also contains (common and non-coding) SNVs that include previously 
identified GWAS loci for all traits, including for BMI and BMI-related traits, reported in the GWAS 
catalogue at the time of its design.  
After removing established loci (+/- 1Mb), the excess of significant associations is markedly 
reduced and inflation reduced (Supplementary Figures 2c and 2d). 
Furthermore, to exclude the possibility that some of the observed associations between BMI and R/LF 
SNVs could be due to allele calling problems in the smaller studies, we performed a sensitivity meta-
analysis with primarily European ancestry studies totaling >5,000 participants. We found very concordant 
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effect sizes, suggesting that smaller studies do not bias our results (Supplementary Figure 12). 
Follow-up Analysis. We sought additional evidence for association of the top signals (P<2.0x10-6) 
identified in the discovery meta-analysis using two independent studies from the UK (UK Biobank, interim 
release, N = 119,613) and Iceland (deCODE, N = 72,613), respectively (Supplementary Tables 1-3). We 
used the same QC and analytical methodology as described above. We used the inverse-variance weighted 
fixed effects meta-analysis in METAL108, to combine the discovery and follow-up association results. 
Significant associations were defined at P < 2×10-7 in the combined meta-analysis of discovery, UK 
Biobank and deCODE results. 
Effect of study design. To investigate the potential effect of study design of the participating studies, we 
tested for heterogeneity between population-based, all case-control studies, T2D case-control studies 
(Supplementary Table 26). None of these comparisons showed significant evidence of heterogeneity 
(P<7.4x10-5, correcting for multiple testing).  
Conditional analyses. The RareMETALS R-package106 was used to identify independent BMI associated 
signals across the all-ancestry meta-analysis results in the discovery phase. RareMETALS performs 
conditional analyses by using covariance matrices from each individual cohort to distinguish true signals 
from the shadows of adjacent significant variants in LD. The conditional associations of all the variants 
within 1Mb of each R/LF coding variant were analyzed to identify [1] nearby secondary signals and [2] to 
determine independence from nearby non-coding variants or previously identified GWAS loci (previously 
defined as a window of 1Mb surrounding the lead SNP). Gene-based conditional analyses were also 
performed in RareMETALS. 
 Due to the selective coverage of variants on the ExomeChip, we also conducted the respective 
conditional analyses in the UK Biobank dataset that included 847,441 genome-wide genotyped markers, 
and 72,355,667 variants imputed against UK10k haplotype reference panel, merged with the 1000 Genomes 
Phase 3 reference panel. Where available, directly genotyped variants where used for conditional analyses. 
Otherwise, imputed variants with good imputation quality (IMPUTE2 info score > 0.6) were used. We used 
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QCTOOL to extract variants of interest from the original imputed data set. Subsequently, GTOOL was used 
to convert to PLINK format (genotype calling threshold 0.99) and merged with the directly genotyped 
variants for conditional analyses in PLINK v1.90b3.35 64-bit (25 Mar 2016). 
Conversions of effect size and explained variants. We assumed that 1 SD = 4.5 kg/m2 BMI-units, 
based on population based data, and 1.7m as the average height of a person to convert effects sizes 
in SD-units into body weight. The variance explained by each variant was calculated using the 
effect allele frequency (f) and beta (β) from the meta analyses using the formula109 of explained 
variance = 2f(1-f)β2. 
Penetrance analysis. We examined the penetrance for the four rare SNVs, p.Arg525Gln (rs56214831) in 
KSR2, p.Tyr35Ter (rs13447324) in MC4R, and p.Arg190Gln (rs139215588) and p.Glu288Gly 
(rs143430880) in GIPR in European ancestry data from the UKBiobank (N up to 120,000). For each variant, 
we compared the prevalence of underweight (BMI < 18.5 kg/m2), normal weight (18.5 kg/m2 ≤ BMI < 25 
kg/m2), overweight (25 kg/m2 ≤ BMI < 30 kg/m2) and obesity (BMI ≥ 30 kg/m2) of non-carriers with non-
carriers. We used a Pearson χ2 test to test for difference between distributions, and a χ2 for linear trend to 
test whether distributions of carriers were shifted compared to non-carriers. For p.Arg525Gln in KSR2 and 
p.Tyr35Ter in MC4R, we hypothesized that obesity prevalence was higher in carriers than in non-carriers, 
whereas for the two GIPR variants, we hypothesized that the prevalence of normal weight was higher in 
carriers than non-carriers.  
Associations with obesity for the coding rare and low-frequency loci in children. For each of the 14 R/LF 
SNVs, we tested for association with childhood obesity in the CHOP cohort (Childhood Obesity: Early 
Programming by Infant Nutrition), the Severe Childhood Onset Obesity Project (SCOOP), the UK 
Household Longitudinal Study (UKHLS) and INTERVAL Study (INTERVAL). Summary statistics across 
the studies were combined using a fixed effects inverse-variance meta-analysis with METAL108. 
In the CHOP study, cases (1,358 boys, 1,060 girls) were defined as having a BMI > 95th percentile 
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at any point in their childhood. Controls (1,412 boys, 1,143 girls) were defined as having < 50th percentile 
consistently through throughout childhood. The BMI percentiles are based on the CDC 2000 Growth 
Charts. All children were classified based on their BMI measurements between the ages of 2 and 18. All 
individuals are of European ancestry and were collected at the Children’s Hospital of Philadelphia. 
Informed consent was obtained from all study participants and study protocols were approved by the local 
ethics committees. Genotypes were obtained using the HumanHap550v1, HumanHap550v3, and 
Human610-Quad high-density SNP arrays from Illumina. The intersection of all SNPs on the arrays was 
used in all subsequent pre-imputation analyses. Before imputation, we excluded SNPs with a Hardy-
Weinberg equilibrium P-value < 1.0×10-6, call rate of < 95% or MAF of < 1%. The genotypes were then 
pre-phased using Shapeit2 and imputed using the 1000 Genomes Phase 1 integrated variant set with 
Impute2. After imputation, SNPs were excluded if the INFO score was < 0.4. Boys and girls were analyzed 
separately using a logistic regression of case and control status, adjusting for three eigenvectors, and 
summary statistics were combined using a fixed effects inverse-variance meta-analysis with METAL108.  
 SCOOP is a sub-cohort of the Genetics Of Obesity Study (GOOS) cohort. It includes >1,500 UK 
European ancestry individuals with severe, early onset obesity (BMI Standard Deviation Score > 3 and 
obesity onset before the age of 10 years), in whom known monogenic causes of obesity have been excluded 
(cases with MC4R mutations were excluded). Two case-control analyses with SCOOP cases were 
performed: 1) SCOOP vs. UKHLS for which array (Illumina HumanCoreExome) data was available, and 
2) SCOOP vs. INTERVAL, for whom whole-exome sequencing data was available.  
For the array based analyses, UKHLS controls were genotyped on the Illumina HumanCoreExome-
12v1-0 Beadchip. SCOOP cases and 48 UKHLS controls were genotyped on the Illumina 
HumanCoreExome-12v1-1 Beadchip. The 48 overlapping UKHLS samples were used for quality control 
to ensure there were no systematic differences and bias between the two versions of the chip. SCOOP and 
UKHLS samples were phased with SHAPEITv2, and imputed with IMPUTE2 using the combined UK10K-
1000G Phase III reference panel. For the WES analyses, SCOOP vs. INTERVAL controls were WES 
within the UK10K-EXOME project (Agilent v3) and the INTERVAL project (Agilent v5) respectively and 
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were then jointly called and QC-ed on the union of the sequencing baits. Individuals overlapping or related 
between the array based and WES studies were removed.  
After QC, 1,456 SCOOP and 6,460 UKHLS (BMI range 19-30), and 521 SCOOP and 4,057 
INTERVAL individuals were available for the two analyses, all were unrelated, of high quality, and of 
European ancestry. For both analyses (i.e. SCOOP vs. UKHLS and SCOOP vs. INTERVAL), a maximum 
likelihood frequentist association test with the additive genetic model was implemented in SNPTEST v2.5. 
In the SCOOP vs. UKHLS analysis, sex and the first six PCs were included as covariates and variants with 
a SNPTEST INFO score <0.4 and HWE p<10-6 were removed. For the SCOOP vs INTERVAL analysis, 
we performed an unadjusted analysis (adjustment for PCs did not change sufficiently the results) and 
variants were limited to those covered at ≥7x in at least 80% of each sequencing cohort, meeting the VQSR 
threshold of –2.52, missingness <80%, HWE P-value<10-8, and GQ ≥30.  
Cross-trait analyses. We evaluated each of the 14 R/LF SNVs for their association with other relevant 
obesity-related traits and conditions. We performed lookups in ExomeChip meta-analysis results from other 
consortia, including, our own GIANT consortium (height15, WHR adjusted for BMI24), MAGIC (HbA1c, 
Fasting Insulin, Fasting Glucose, 2-hour glucose), GLGC (HDL-cholesterol (HDL-C), LDL-cholesterol 
(LDL-C), triglycerides and total cholesterol)), IBPC40 (systolic and diastolic blood pressure), 
REPROGEN23 (age at menarche and menopause) and GoT2D/T2D-GENES16 (type 2 Diabetes). 
Associations were considered significant at P < 2.0×10-5, accounting for multiple testing. 
Phenome-wide association analysis (PheWAS). To evaluate the potential for pleiotropic effects for SNPs 
discovered from primary analyses, we performed phenome-wide association studies (PheWASs) using 
genotype and phenotype data from two independent sources of electronic health records (EHR): Vanderbilt 
University Medical Center Biorepository (BioVU) and the United Kingdom BioBank (UKBB). Phenotype 
selection and analysis strategy were synchronized across sites. A total of 1502 hierarchical phenotype codes 
from EHRs were curated by grouping International Classification of Disease, Ninth Revision (ICD-9) 
clinical/billing codes as previously described110. Phenotype codes with 20 or more cases and with minor 
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allele count of 5 or greater in cases and controls were eligible for analysis. Series of logistic regression 
analyses were then performed in individuals of European ancestry for each eligible phenotype-genotype 
combination while adjusting for 5 genetic ancestry PCs. Odds ratios from genotype-phenotype 
combinations present in both BioVU and UKBB were then aggregated using inverse-variance weighted 
fixed-effects meta-analysis. Associations with p-values corresponding to false discovery rate (FDR) cut off 
of less than 10% were considered statistically significant. 
Gene set enrichment analysis. We adapted DEPICT, a gene set enrichment analysis method for GWAS 
data, for use with the ExomeChip (‘EC-DEPICT’). DEPICT’s primary innovation is the use of 
“reconstituted” gene sets, where many different types of gene sets (e.g. canonical pathways, protein-protein 
interaction networks, and mouse phenotypes) were extended through the use of large-scale microarray data 
(see111 for details). EC-DEPICT computes P-values based on Swedish ExomeChip data (Malmö Diet and 
Cancer [MDC], All New Diabetics in Scania [ANDIS], and Scania Diabetes Registry [SDR] cohorts, 
N=11,899) and, unlike DEPICT, takes as input only coding variants and only the genes directly containing 
those variants, rather than all genes within a specified amount of linkage disequilibrium (Supplementary 
Note). 
 Four analyses were performed for the BMI EC variants: [1] all coding variants with P<5x10-4, [2] 
all coding variants with P<5x10-4 independent of known GWAS variants5, [3] all coding R/LF variants with 
P<5x10-4, and [4] all coding R/LF variants with P<5x10-4 independent of known GWAS variants. Affinity 
propagation clustering3 was used to group highly correlated gene sets into “meta-gene sets”. For each meta-
gene set, the member gene set with the best P-value was used as representative for purposes of visualization 
(Supplementary Note). DEPICT for ExomeChip was written using the Python programming language 
(See URLs).  
Drosophila RNAi knockdown experiments. For each of the 13 genes in which R/LF coding variants were 
associated with BMI, we searched for its corresponding orthologues in Drosophila in the ENSEMBL 
orthologue database. Orthologues were available for nine genes, but missing for ZBTB7B, MC4R, GIPR, 
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and ZNF169. For each of the nine genes, we generated adipose-tissue (cg-Gal4) and neuronal (elav-Gal4) 
specific RNAi-knockdown crosses, leveraging upstream activation sequence (UAS)-inducible short-hairpin 
knockdown lines, available through the Vienna Drosophila Resource Center (VDRC). We crossed male 
UAS-RNAi flies and elav-GAL4 or CG-GAL4 virgin female flies. All fly experiments were carried out at 
25 °C. Five-to-seven-day-old males were sorted into groups of 20, weighed and homogenated in PBS with 
0,05% Tween with Lysing Matrix D in a beadshaker. The homogenate was heat-inactivated for 10 min in 
a thermocycler at 70 °C. 10µl of the homogenate was subsequently used in triglyceride assay (Sigma, Serum 
Triglyceride Determination Kit) which was carried out in duplicates according to protocol, with one 
alteration: the samples were cleared of residual particulate debris by centrifugation before absorbance 
reading. Resulting triglyceride values were normalized to fly weight and larval/population density. We used 
the non-parametric Kruskall-Wallis test to compare wild type with knockdown lines. 
Enrichment analysis in monogenic genes of obesity. We identified 39 genes with strong evidence that 
disruption causes monogenic or syndromic forms of obesity (Supplementary Table 21). To test whether 
these genes are enriched for R/LF coding variant associations with BMI, we conducted simulations by 
matching each of the 39 genes with other genes based on gene length and number of variants tested, to 
create a matched set of genes. We generated 1,000 matched gene sets from our data and assessed how often 
the number of R/LF coding variants that exceeded given significance thresholds was greater in our 
monogenic/syndromic obesity gene set compared to the matched gene sets. 
 
DATA AVAILABILITY 
Summary statistics can be downloaded from 
http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium 
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1. COMMON CODING VARIANTS ASSOCIATED WITH BMI 
The main focus of our study was the analysis of the 215,917 rare and low frequency (R/LF) coding 
variants, which are more likely to disrupt protein function1,2. However, besides R/LF coding 
variants, the ExomeChip also carries 13,786 common coding SNVs, which were also tested for 
association with BMI as part of the study.  
We identified 41 novel loci that showed association with BMI (AWS: P<2.0x10-7), 
independent from any previously identified loci (Supplementary Table 4, Supplementary Figure 
4). The reasons why these 41 novel loci has not been reported by previous large-scale GWAS 
before are; the sample size of the current study is more than twice as large as the most recent 
GWAS3, thus providing greater statistical power for discovery, and/or SNPs may not have been 
tested in previous GWAS efforts because they were not available in HapMap, and thus not 
imputed, SNPs did not pass quality control, or are located on the X-chromosome, which has so 
far not been considered in GWAS. 
We also identified common variants that clustered in 51 loci that had been identified before 
(<1Mb previous GWAS lead SNP) in large-scale GWAS efforts of adiposity traits (Supplementary 
Table 4, Supplementary Figure 4). Using conditional analyses (Online Methods), we were able 
to show that 38 of these 51 loci represent the same locus as the one identified before and one 
represents an independent secondary signal in the previously established locus. For the 
remaining 12 loci, we were not able to confirm whether the association represented secondary or 
the same signal within the established locus because the original SNP (or proxy) was not available 
on the ExomeChip to perform conditional analyses (Supplementary Table 4, Supplementary 
Figure 4).  
Effect sizes of the 41 novel loci are smaller (on average 0.014 SD/allele, [range: 0.010 – 
0.024 SD/allele]) than those of the 37 previously established loci (average 0.021 SD/allele, [range: 
0.010 – 0.050 SD/allele]) (Supplementary Figure 5). This difference is likely due to the increased 
sample size (N>700,000), and thus power, of our meta-analyses, compared to sample size of 
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previous GWAS efforts (N up to 340,000), allowing the identification of loci with smaller effects. 
Signals in established loci, for which conditional analyses could not convincingly determine 
whether it was a secondary observation, have effect sizes in between the novel and established 
loci (average 0.016 SD/allele, [range: 0.010 – 0.030 SD/allele]). The explained variance of the 41 
novel loci ranges between 0.004% and 0.02%, and add up to a combined explained variance of 
0.394%, as compared to the 2.7% of the variance explained by the 97 loci reported in our latest 
GWAS BMI effort3.    
The novel common coding loci have features similar to those of previously established 
GWAS loci; i.e. they represent a cluster of variants in high LD with each other that require further 
fine-mapping efforts to identify the causal genes/variants in the locus. The common coding 
variants, including those that reached P<5x10-4, were included in the EC-DEPICT analyses and 
results are described in the Main text.   
 
2. COMPARISON OF NOVEL COMMON, LOW FREQUENCY AND RARE VARIANTS ACROSS ANCESTRIES 
2.1. Low-frequency and rare coding SNVs 
We observed no significant heterogeneity in effect sizes across ancestries, accounting for multiple 
testing across novel SNVs (P threshold = 9x10-4 = 0.05/(14+41)), which may in part be due to low 
statistical power in non-European ancestry populations (Supplementary Table 7, 
Supplementary Figure 6). Minor allele frequencies are general consistent across ancestries, 
with two exceptions. The minor allele of rs7636 (p.Pro477Pro) in ACHE is of low frequency in 
European ancestry populations (4.2%), but much more common in African (24.4%) and Hispanic 
(9.9%) ancestry populations and, similarly, that of rs12236219 in ZNF169 is of low frequency in 
European ancestry populations, but common in all other ancestries studied.   
Of interest are the two SNVs (p.His353Asn, p.Pro477Pro) in ACHE, which track together 
nearly perfectly in European ancestry populations (r2=0.98; D’=0.99, MAFs=4.2%), whereas in 
African ancestry populations they are not correlated (r2=0.01; D’=0.95). In the African ancestry 
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data, the non-synonymous SNV p.His353Asn is rare (0.60%) and has a similar estimated effect 
size (0.057 SD/allele, 95% CI [-0.050-0.164], P=0.29) to the effect seen in European ancestry 
individuals (0.034 SD/allele, 95% CI [0.023-0.044]), whereas the synonymous p.Pro477Pro is 
common (24.4%) and has no detectable effect on BMI (-0.006 SD/allele, P=0.56). Even though 
our sample size was relatively small, an effect of 0.023-0.044 SD/allele, as observed in European 
ancestry individuals, would have been detectable in our African-ancestry population 
(MAF=24.4%, N~24,000, power ~80%, at α=0.01). The absence of such association suggests 
that p.Pro477Pro may not be driving the association at this locus and that p.His353Asn (or 
potentially a variant correlated with p.His353Asn, but not with p.Pro477Pro, in African-ancestry 
populations) is more likely to be the causal variant. This is consistent with functional role of many 
non-synonymous, as compared to synonymous variants. 
2.2. Novel common SNVs 
None of the 41 novel commons SNVs showed evidence of heterogeneity across ancestries 
(Pthreshold = 9x10-4). Generally, allele frequencies of the BMI-increasing allele in European 
ancestry populations were consistent with those of South Asian (r2 = 0.82) and Hispanic (r2 = 
0.86) ancestry populations, and somewhat lower with African (r2 = 0.52) and East Asian (r2 = 0.48) 
ancestries (Supplementary Table 7, Supplementary Figure 6). Because of the relatively small 
sample sizes of non-European ancestry populations, statistical power for replication of 
associations observed in the total sample or European ancestry only meta-analyses was low. 
Nevertheless, of the 41 SNVs, associations were directionally consistent for 32 SNVs (78%), of 
which 7 reached nominal significance, in the African ancestry meta-analysis (Supplementary 
Table 7, Supplementary Figure 6). The directional consistency between European ancestry 
associations was similar for South Asian (34 SNVs (83%) of which 5 nominally significant) and 
Hispanic (34 SNVs (83%) of which 3 nominally significant) ancestry populations, and lower for 
East Asian ancestry populations (61 SNVs (61%) of which 6 nominally significant). 
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3. GENE SET ENRICHMENT ANALYSIS (EC-DEPICT) 
DEPICT is a method for gene set enrichment analysis and gene prioritization of GWAS data4. 
Briefly, 14,462 gene sets from KEGG5, REACTOME6, Gene Ontology7, InWeb8 (protein-protein 
networks) and Mouse Phenotype9 databases were obtained and “reconstituted” using large-scale 
microarray data, based on the logic of guilt-by-association (genes with similar patterns of 
expression are more likely to be members of the same gene sets). We have adapted the gene 
set enrichment functionality of DEPICT for the ExomeChip (EC-DEPICT), with a few alterations: 
(1) instead of including all genes within a specified amount of linkage disequilibrium to each index 
SNP, we include only the gene containing the index SNV, (2) we include only nonsynonymous 
and splicing (coding) SNVs, discarding noncoding associations and (3) we use null ExomeChip 
data for p-value calculation (rather than null GWAS data). In this supplement, we provide a brief 
overview of the method and more detailed explanations of each analysis. 
3.1. Method 
The EC-DEPICT method has been described elsewhere10. We generated null ExomeChip data 
from the Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS), and Scania 
Diabetes Registry (SDR) cohorts (a total of 11,899 samples with Swedish ancestry). After 
generating simulated normally-distributed phenotypes, we conducted 2,200 null ExomeChip 
association studies, filtering out all variants not present in the BMI association study. The variants 
in each null study were then sorted by ascending P-value and clumped (+/- 1 Mb on each side). 
Annotations from the CHARGE consortium were used to assign variants to genes (see URLs). 
For analyses of rare/low-frequency variants, a separate set of backgrounds was created that 
retained only loci where the index SNV had a minor allele frequency of <5%. 
The method for gene set enrichment is as follows. A list of significant input variants from 
the ExomeChip is obtained (index SNVs for each locus, coding variants only) and filtered to 
remove variants not present in the null backgrounds or that are not marked as 
nonsynonymous/splice-site in the CHARGE consortium annotations. Then, we map the variants 
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to genes. For each gene set, we then calculate a test statistic: the sum of gene set membership 
z-scores from the reconstituted gene sets1 for the input genes. We then take 2000 nulls and 
compute the average (null) test statistic and standard deviation for the given gene set (where the 
number of top genes we take from each null as “input genes” is matched to the observed number 
of input genes). A z-score for the gene set is then computed as the observed test statistic minus 
the null test statistic divided by the null standard deviation, which is converted to a p-value based 
on the normal distribution. False discovery rates (FDRs) were calculated using an additional 50 
null permutations to generate a distribution of null p-values. The FDR was calculated as the 
average number of null p-values less than a given threshold divided by the number of observed 
p-values less than that threshold. 
Our null data (MDC, ANDIS, and SDR cohorts) was also used for the ExomeChip analysis 
of height10. As in the height analysis, before gene set enrichment analysis of BMI-associated 
variants, we removed variants absent in this null ExomeChip data. This resulted in exclusion of 
about 30% of the BMI-associated variants at suggestive of array-wide significance. Most of the 
excluded variants were in the very rarest allele frequency bins, and mostly reached suggestive 
rather than array-wide significance. The exclusion of the rarest variants is expected due to the 
much smaller sample size of the null cohorts relative to the BMI data. To try to include more 
variants in the analysis, we also generated null ExomeChip data based on the UK Biobank, which 
resulted in the exclusion of fewer BMI-associated variants (due to the much larger sample size of 
the UK Biobank data). However, we observed that use of these null data, despite including more 
of the rarest BMI-associated variants in the gene set enrichment analysis, dampened the signal 
and resulted in fewer significantly enriched gene sets. This result suggests that 1) the rarest 
variants are more likely to have a lower true positive rate and/or 2) the heterogeneity of the 
underlying biology increases with the inclusion of very rare variants. 
Although some variants were excluded from the EC-DEPICT analysis, we have included 
them in the heatmap figures (Figure 2, Supplementary Figure 10). This is because we assume 
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that if the genes containing those variants have strong predicted membership in gene sets 
found to be significantly enriched, they are still good candidates for prioritization (and one of the 
main purposes of the heatmap strategy is to visually prioritize the best candidate genes). In fact, 
this is arguably even stronger evidence for prioritization of these genes, because they had no 
opportunity to influence the gene sets that are identified as enriched and, as such, 
independently support the biology implicated by these gene sets. 
We have observed that extreme non-normality of gene set membership z-scores can, in 
certain situations, cause minor inflation of Type I error. To address this issue, we repeated the 
original EC-DEPICT analysis with an inverse-normal-transformed version of the reconstituted 
gene sets, in which every gene set is forced to have a normal z-score distribution for pathway 
membership. We then compared the rank of each significant gene set in the original results with 
the rank in the inverse normal transform and flagged “outliers” with respect to the change in rank 
(> 1.5 * the interquartile range). In visualizing the results with heat maps and in supplementary 
tables, outlier gene sets were excluded.  
3.2. Analyses 
We performed four different analyses of the BMI-associated variants. In each case, for each locus, 
we included the best coding variant, including secondary signals if present. “GWAS-independent” 
analyses were performed by excluding EC loci conditionally dependent on or <1 Mb away from a 
known GWAS locus (see below for details). For this purpose, “known loci” consisted of a list of all 
variants used as input in the original DEPICT analysis in Locke et al.3 (P<5x10-4). This was 
necessary to confirm true independence from the original DEPICT findings (i.e. gene set 
enrichment results for EC that come from a completely non-overlapping set of genes relative to 
the original DEPICT analysis). 
The breakdown of included variants is as follows. Array-wide significant variants (P<2x10-
7) came from the final meta-analysis of Discovery, deCODE, and UK Biobank results across all 
analysis strata. For these variants (“stringent”), independence from genome-wide significant 
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GWAS loci was determined by conditional analysis. Additional variants with p-values between 
5x10-4 and 2x10-7 (“relaxed”) were based on Discovery in the all-ancestries sex-combined additive 
model. For these variants, independence from genome-wide significant GWAS loci was based on 
a distance of >1 Mb. For both stringent and relaxed variants, independence from marginally 
significant GWAS loci was also based on a distance of > 1 Mb. All loci were clumped +/- 1 Mb. 
For the first analysis, we included all EC loci with p<5x10-4. After filtering, this left 244 
variants in 242 genes; we discovered 67 gene sets (24 meta-gene sets) at FDR <0.05. After 
removing inverse normal transform outliers (see description above), that left 62 gene sets (still in 
24 meta-gene sets). The second analysis included EC loci with 5x10-4 “independent” of a known 
GWAS locus3 (110 variants in 110 genes after filtering). We found no significant gene sets in this 
analysis.  
The third and fourth analyses included rare and low-frequency (RLF; <5% MAF) variants 
only. The third analyses included all RLF variants with P<5x10-4, representing a total of 50 variants 
in 50 genes after filtering. We found 512 significant gene sets at FDR <0.05 (107 meta-gene sets). 
After applying the inverse normal transform filter, this was reduced to 471 significant gene sets in 
106 meta-gene sets. Finally, the last analysis included RLF variants with P<5x10-4 “independent” 
of a known GWAS locus3 (after filtering, 30 variants in 30 genes). This recovered 31 significant 
gene sets in 12 meta-gene sets at FDR <0.05. After the inverse normal transform, we retained 29 
significant gene sets, still in 12 meta-gene sets. 
3.3. Affinity propagation clustering 
To collapse the most highly correlated gene sets, affinity propagation clustering was performed 
as described in Marouli et al. (2017)10. Briefly, “meta-gene sets” were generated by affinity 
propagation clustering3 of all pairs of 14,462 gene sets, using SciKit-
Learn.clustering.AffinityPropagation version 0.1711, with a maximum iteration of 10,000 and a 
convergence iteration of 1,000. For each meta-gene set, P-values were assigned based on the 
most significant member gene set (considered the “best representative gene set”). In heat maps, 
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z-scores for meta-gene set membership represent the z-score of the best representative gene 
set. Heat maps were generated with the ComplexHeatmap package in R12. For Online Mendelian 
Inheritance in Man (OMIM) annotations, a manual curation of obesity-related terms in the OMIM 
database was performed. 
3.4. URLs 
CHARGE Consortium ExomeChip annotation file: 
http://www.chargeconsortium.com/main/exomechip/  
EC-DEPICT: https://github.com/RebeccaFine/obesity-ec-depict 
EC-DEPICT meta-gene sets: https://github.com/RebeccaFine/obesity-ec-
depict/blob/master/data/metacluster_labels.txt 
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4. SUPPLEMENTARY FIGURES 
Supplementary Figure 1 | Flowchart of the GIANT ExomeChip BMI study design. 
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Supplementary Figure 2 | Quantile-quantile plots of BMI associations for coding SNVs tested in the Discovery GIANT meta-
analyses. A-B. Quantile-quantile plots of BMI associations tested in all-ancestries (A) and European ancestry (B) strata for all coding 
(exonic and splicing) SNVs in black, and stratified by minor allele frequency (MAF) cut-offs; common variants (MAF≥5%) in green, rare 
and low-frequency variants (MAF<5%) in dark blue, and rare variants (MAF<1%) in light blue. C-D. Quantile-quantile plots of BMI 
associations tested in all-ancestries (C) and European ancestry (D) strata for all coding (exonic and splicing) SNVs in black, and after 
excluding (±1Mb) known and novel loci identified in previous BMI GWAS and in the ExomeChip meta-analysis (pink).  
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Supplementary Figure 3 | Manhattan plots of coding rare and low-frequency SNV associations in the Discovery GIANT dataset 
appended with the significant SNVs from the final combined meta-analysis. Manhattan plot of associations in all-ancestries sex-
combined additive (A), all-ancestries women additive (B) and European ancestry sex-combined additive (C) strata. Each locus was 
defined using a 1Mb window on each side of the lead coding variant. Dots correspond to the Discovery GIANT meta-analysis results, 
while the final combined meta-analysis results were appended to the plots using triangles. Only significant loci in the final combined 
meta-analysis were colored; novel loci, secondary signals (in known GWAS loci, but independent from GWAS hit/proxy) and known 
loci were highlighted in red, light blue and dark blue, respectively.  
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Supplementary Figure 4 | Manhattan plots of coding common SNV associations obtained in the Discovery GIANT dataset 
appended with the significant SNVs from the final combined meta-analysis See also Supplementary Table 4 for detailed results. 
Each locus was defined using a 1Mb window on each side of the lead coding variant. Dots correspond to the Discovery GIANT meta-
analysis results, while the final combined meta-analysis results were appended to the plots using triangles. 
Panels A, B & C: Results from novel loci and novel secondary signals. Manhattan plot of associations in all-ancestries sex-
combined additive (A), all-ancestries sex-combined recessive (B) and European ancestry sex-combined additive (C) strata. Only novel 
loci (in red) and novel secondary signals in known loci (in cyan) are shown in panels A, B & C.  
Panels D & E: Results from known loci, some of which with potential secondary signals. Manhattan plot of associations in all-
ancestries sex-combined additive (D) and all-ancestries women additive (E) strata. Loci that were previously established (in blue), and 
signals in previously known loci, but for which conditional analyses could not convincingly determine whether the signal was secondary 
or the same locus (in grey) are shown in panels D & E.  
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Supplementary Figure 5 | Regional association plots for the significant rare and low-
frequency coding loci identified in the final combined meta-analysis among all analysis 
strata. The association results shown in these plots are from the Discovery GIANT meta-analysis 
in the specified analysis strata for all ExomeChip SNVs (dots) and appended with the previous 
BMI GWAS results (European ancestry) from Locke et al. (crosses; Locke et al. Nature 518, 197-
206). The size of the dots and crosses are weighted on the minor allele frequency. We have used 
the UK Biobank dataset (European ancestry; N=136,727) to calculate the linkage disequilibrium 
between the SNVs in the window and the reference coding SNV shown in turquoise. Only GWAS 
traits related with body weight are shown in the plots. (A) Regional plots for loci with only one 
significant coding SNV in the region (only unconditioned results shown). (B) Regional plots for 
loci with more than one significant coding SNVs or with a GWAS hit or proxy (r2>0.80 in EUR 
1000G phase 3) in the region (<±1MB). Both unconditioned and conditioned results are shown.   
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ZFR2 - All-ancestries women additive 
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ACHE - All-ancestries sex-combined additive B 
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GIPR - All-ancestries sex-combined additive 
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ENTPD6 - All-ancestries sex-combined additive 
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Supplementary Figure 6 | Relationship of allele frequencies and effect sizes of novel SNVs between European-ancestry and 
other ancestry populations (see also Supplementary Table 7). Panel A shows the data for the minor alleles of 14 low-frequency and 
rare SNVs. Panel B shows the data for the BMI-increasing allele of the 41 common SNVs.  
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Supplementary Figure 7 | Effect sizes (y-axis) of the 92 common coding variants by their 
BMI-increasing allele frequency. Effect sizes are expressed in SD per allele (Supplementary 
Table 4). Blue dots represent the 42 novel loci, orange dots represent loci that have been 
identified before in GWAS for obesity traits, and green dots represent association signals in 
previously established loci, but for which conditional analyses was not able to convincingly 
determine the signal as secondary or not (i.e. the previously established lead SNP was not 
available on the chip).  
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Supplementary Figure 8 | Effects of the two rare SNVs (p.Arg190Gln, p.Glu288Gly) in GIPR 
on BMI in the UK Biobank (N = 115,611, Interim release). Y-axis shows the difference from 
mean BMI in the UKBiobank, after adjusting for age and sex. 
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Supplementary Figure 9 | Heatmaps of cross-trait associations for the novel R/LF 
independent loci identified in the final combined meta-analysis. Heatmap squares are –
log10(P-values) with red-to-blue shading based on beta effect direction for the BMI-increasing 
allele in the final combined meta-analysis (blue). Green-to-blue shading hits correspond to 
positive beta effects with P-values between 0.05 and <2E-5, orange-to-red shading hits 
correspond to negative beta effects with P-values between 0.05 to <2E-5, yellow squares are not 
significant (P>0.05), and white squares are missing values. Clustering was done using the 
complete linkage method with Euclidean distance measure for the loci. SNVs clustering together 
are more significantly associated with the same set of traits.  
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Supplementary Figure 10 | Heatmaps showing full DEPICT gene set enrichment results A) of rare and low frequency 
nonsynonymous SNVs (from main text figure 2), B) of novel rare and low frequency nonsynonymous SNVs, and C) 
nonsynonymous SNVs of all allele frequencies. For any given square, the color indicates how strongly the corresponding gene 
(shown on the x-axis) is predicted to belong to the reconstituted gene set (y-axis). This value is based on the gene’s z-score for gene 
set inclusion in DEPICT’s reconstituted gene sets, where red indicates a higher and blue a lower z-score. To visually reduce redundancy 
and increase clarity, we chose one representative "meta-gene set" for each group of highly correlated gene sets based on affinity 
propagation clustering (Online Methods, Supplementary Information). Heatmap intensity and DEPICT P-values (see P-values in 
Supplementary Tables 17-19) correspond to the most significantly enriched gene set within the meta-gene set. Annotations for the 
genes indicate (1) whether the gene has an OMIM annotation as underlying a monogenic obesity disorder (black and grey), (2) the 
minor allele frequency of the significant ExomeChip (EC) variant (shades of blue; if multiple variants, the lowest-frequency variant was 
kept), (3) whether the variant’s P-value reached array-wide significance (<2x10-7) or suggestive significance (<5x10-4) (shades of 
purple), (4) whether the variant was novel, overlapping “relaxed” GWAS signals from Locke et al.3 (GWAS P<5x10-4), or overlapping 
“stringent” GWAS signals (GWAS P<5x10-8) (shades of pink), and (5) whether the gene was included in the gene set enrichment 
analysis or excluded by filters (shades of brown/orange) (Online Methods and Supplementary Information). Annotations for the 
gene sets indicate if the meta-gene set was found significant (shades of green; FDR <0.01, <0.05, or not significant) in the DEPICT 
analysis of GWAS results from Locke et al.3 
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Supplementary Figure 11 | Quantile-quantile plot for BMI associations for rare and low-
frequency coding SNVs located in monogenic and syndromic genes of obesity. Single 
variant association results obtained in the final combined meta-analysis are enriched for coding 
SNVs located in monogenic and syndromic genes of obesity (see gene list and results in 
Supplementary Table 21).  
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Supplementary Figure 12 | Scatter plot comparison of the effect sizes for all variants that 
reached significance in the European-ancestry-discovery results (n = 526,508) and results 
including only studies with sample sizes of more than 5,000 individuals (n = 317,511). 
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